These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 2608950)
1. TOX-RISK: a program for fitting dose-response formulae and extrapolating between species. Crouch EA Risk Anal; 1989 Dec; 9(4):599-603. PubMed ID: 2608950 [No Abstract] [Full Text] [Related]
2. The mathematics of drug dose individualization should be built with random-effects linear models. Diaz FJ; de Leon J Ther Drug Monit; 2013 Apr; 35(2):276-7. PubMed ID: 23503456 [No Abstract] [Full Text] [Related]
3. Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models". Holford NH; Buclin T Ther Drug Monit; 2013 Dec; 35(6):873-4. PubMed ID: 24263647 [No Abstract] [Full Text] [Related]
4. Current issues with regard to single dose toxicity studies. Hashimoto M J Toxicol Sci; 1996 Dec; 21(5):417-20. PubMed ID: 9035048 [No Abstract] [Full Text] [Related]
5. Drugs with aging. Misperceptions about medications. Mayo Clin Health Lett; 2014 Dec; 32(12):7. PubMed ID: 26087529 [No Abstract] [Full Text] [Related]
6. Is current drug safety an issue? Besag FM Curr Drug Saf; 2007 Jan; 2(1):1-4. PubMed ID: 18690943 [No Abstract] [Full Text] [Related]
7. Guidelines for experiments to predict the degree of safety of a material for man. Weil CS Toxicol Appl Pharmacol; 1972 Feb; 21(2):194-9. PubMed ID: 5023833 [No Abstract] [Full Text] [Related]
8. Ways to minimize adverse drug reactions. Individualized doses and common sense are key. Cohen JS Postgrad Med; 1999 Sep; 106(3):163-8, 171-2. PubMed ID: 10494273 [TBL] [Abstract][Full Text] [Related]
9. FDA mulls changes to bioequivalence standards. Traynor K Am J Health Syst Pharm; 2010 Jun; 67(11):864. PubMed ID: 20484205 [No Abstract] [Full Text] [Related]
10. Drugs and the kidney: more than a question of dose. Waller DG Br J Clin Pharmacol; 2007 Dec; 64(6):719-21. PubMed ID: 18078474 [No Abstract] [Full Text] [Related]
11. A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity. Kuepfer L; Clayton O; Thiel C; Cordes H; Nudischer R; Blank LM; Baier V; Heymans S; Caiment F; Roth A; Fluri DA; Kelm JM; Castell J; Selevsek N; Schlapbach R; Keun H; Hynes J; Sarkans U; Gmuender H; Herwig R; Niederer S; Schuchhardt J; Segall M; Kleinjans J Arch Toxicol; 2018 Jan; 92(1):553-555. PubMed ID: 28852801 [No Abstract] [Full Text] [Related]
15. Role of the clinical pharmacologist in teaching therapeutics. Hayes AH J Clin Pharmacol; 1975 Apr; 15(4 Pt 1):213-20. PubMed ID: 1127126 [No Abstract] [Full Text] [Related]
16. Deficiencies in our present protocol for chemical evaluation and possible remedies. Legator MS Ann N Y Acad Sci; 1971 Jul; 179():508-13. PubMed ID: 5285390 [No Abstract] [Full Text] [Related]
17. Drug metabolism and metabolite safety assessment in drug discovery and development. He C; Wan H Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280 [TBL] [Abstract][Full Text] [Related]
18. Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets. Clark AM; Dole K; Coulon-Spektor A; McNutt A; Grass G; Freundlich JS; Reynolds RC; Ekins S J Chem Inf Model; 2015 Jun; 55(6):1231-45. PubMed ID: 25994950 [TBL] [Abstract][Full Text] [Related]
19. Adverse Drug Reactions: Type A (Intrinsic) or Type B (Idiosyncratic). Iasella CJ; Johnson HJ; Dunn MA Clin Liver Dis; 2017 Feb; 21(1):73-87. PubMed ID: 27842776 [TBL] [Abstract][Full Text] [Related]
20. A scientific rationale for choosing patients rather than normal subjects for Phase I studies. Oates JA Clin Pharmacol Ther; 1972; 13(5):809-11. PubMed ID: 5054325 [No Abstract] [Full Text] [Related] [Next] [New Search]